A Phase 1, Single-Center, Pacritinib- Versus Placebo-Blinded, Active- and Placebo-Controlled, Randomized, 3-Way Crossover Study to Evaluate the Cardiac Safety and Pharmacokinetics Following a Single Oral Dose Administration of Pacritinib in Healthy Subjects

Trial Profile

A Phase 1, Single-Center, Pacritinib- Versus Placebo-Blinded, Active- and Placebo-Controlled, Randomized, 3-Way Crossover Study to Evaluate the Cardiac Safety and Pharmacokinetics Following a Single Oral Dose Administration of Pacritinib in Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Sep 2016

At a glance

  • Drugs Pacritinib (Primary)
  • Indications Acute myeloid leukaemia; Chronic myeloid leukaemia; Colorectal cancer; Haematological disorders; Myelodysplastic syndromes; Myelofibrosis; Myeloproliferative disorders
  • Focus Adverse reactions
  • Sponsors CTI BioPharma
  • Most Recent Events

    • 25 Jun 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top